Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Capsulution Nanoscience AG on the Upswing

Abstract:
Berlin-based Nanotechnology Company fulfills revenue expectations.

Capsulution Nanoscience AG on the Upswing

Berlin, Germany | Posted on February 23rd, 2007

The Berlin-based Capsulution Nanoscience AG fulfilled its turnover expectations
in 2006 with more than 1.3 million euro. In comparison to the year before,
the developer of nanotechnological „active component packages‰ managed with
this an increase of about 50 %. The personnel figures rose to a final 20
members of staff, more than half of which are highly-qualified scientists
and laboratory staff in the field of research and development.

As well as carrying out numerous customer projects, Capsulution has
undertaken vital steps to test its own technology in preclinical studies and
adapt to the requirements of industrial customers, evident in its
collaboration with the Charité, started at the end of 2006. Due to such
preliminary developments, the EBIT margin with about TEUR -150 still turned
out negatively. "With this operational result, our company is clearly faring
better than many other start-up technology companies in the same field,"
states Alexander Herrmann, CFO.

Herrmann is optimistic about the year to come: " Our aim is not only to
increase the turnover to double figures but also to break even." These high
expectations are based not in the least on the positive developments of the
past months. Since November, Capsulution has, with the additional granting
of its basis patent for its LBL Technology yet another competitive edge on
the competition.

Speaking for the good growth prognoses are further well-known partner and
customer acquisitions with commissioned developments in innovative
nanoproducts forged in the last year, such as the published developments
with the Schering AG (today Bayer Schering Pharma AG) or the Eyesense AG.

####

About Capsulution Nanoscience AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on
the development of tailor-made drug delivery systems and other innovative
life science products based on tunable nano-sized capsules. The company
applies its worldwide-patented so-called LBL-Technology®. Based on their
minute size, their functionality and their highly reproducible production
process the tunable capsules can be used for a multitude of different
applications. Accordingly, the precisely sized capsules can be made to
function in a manner to suit the intended application, and can be given the
appropriate biochemical, electrical, optical and magnetic properties as
required by the customer. In order to meet customers needs for complete
product solutions Capsulution has recently designated EBARA Corp. as the
preferred developer, manufacturer and distributor for automated LBL-units.
Only six month after the signing of the licence agreement, EBARA has started
operation of the first prototype plant (LBL-Unit®) for the manufacture of
Capsulution's LBL capsules.

For more information, please click here

Contacts:
Herr Dipl.-Kfm. Alexander Herrmann
e-mail:
Phone: +49 (0)30-670 6919-0
Fax: +49 (0)30-670 69 19-101

Copyright © Capsulution NanoScience AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

Announcements

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Financial Reports

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016

Nanobiotix revenue for Q2 2016 July 14th, 2016

Nanometrics to Announce Second Quarter Financial Results on July 26, 2016 July 6th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project